Company Filing History:
Years Active: 2002-2003
Title: Innovator in Pharmacotherapy: Phillip R. Nixon
Introduction
Phillip R. Nixon, a talented inventor based in Portage, MI, has made significant contributions to the field of pharmacotherapy. With a focus on enhancing the administration of the medication reboxetine, he has secured two essential patents that showcase his innovative approach to drug delivery systems.
Latest Patents
Nixon's most notable patents revolve around methods for providing effective reboxetine therapy with once-a-day dosing. The sustained release dosage forms he developed are designed to achieve therapeutically effective average steady-state plasma reboxetine concentrations when administered once daily. This innovative dosing regimen results in a singular peak plasma reboxetine concentration occurrence within each 24-hour period, providing a more controlled therapeutic effect. Moreover, the peak plasma concentration occurs later and exhibits a lesser magnitude compared to immediate-release dosage forms, making it a promising solution for patients requiring steady medication management.
Career Highlights
Throughout his career at Alza Corporation, Phillip R. Nixon has demonstrated exceptional technical expertise and a commitment to advancing pharmaceutical science. His work has played a pivotal role in improving patient outcomes through enhanced medication delivery systems. Nixon's focus on patient-centered innovation underscores his dedication to the pharmaceutical field.
Collaborations
Nixon has collaborated with esteemed colleagues such as Sylvia L. Seroff and Noymi Yam, enhancing the collaborative nature of research and innovation at Alza Corporation. These partnerships have allowed for the exchange of ideas and expertise, ultimately leading to groundbreaking advancements in medication delivery technologies.
Conclusion
Phillip R. Nixon's contributions to the field of pharmacotherapy are underscored by his innovative patents and collaborative spirit. His work not only reflects his ingenuity as an inventor but also highlights the potential for significant advancements in patient care through sustained-release drug formulations. Through his continued efforts at Alza Corporation, Phillip R. Nixon is well-positioned to influence the future of pharmaceutical innovations.